vs

Side-by-side financial comparison of Cycurion, Inc. (CYCU) and IMMUCELL CORP (ICCC). Click either name above to swap in a different company.

IMMUCELL CORP is the larger business by last-quarter revenue ($5.5M vs $3.5M, roughly 1.6× Cycurion, Inc.). IMMUCELL CORP runs the higher net margin — -2.5% vs -141.2%, a 138.7% gap on every dollar of revenue. On growth, IMMUCELL CORP posted the faster year-over-year revenue change (-8.4% vs -13.1%). IMMUCELL CORP produced more free cash flow last quarter ($-1.8M vs $-3.5M). Over the past eight quarters, IMMUCELL CORP's revenue compounded faster (3.9% CAGR vs -8.6%).

ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.

CYCU vs ICCC — Head-to-Head

Bigger by revenue
ICCC
ICCC
1.6× larger
ICCC
$5.5M
$3.5M
CYCU
Growing faster (revenue YoY)
ICCC
ICCC
+4.7% gap
ICCC
-8.4%
-13.1%
CYCU
Higher net margin
ICCC
ICCC
138.7% more per $
ICCC
-2.5%
-141.2%
CYCU
More free cash flow
ICCC
ICCC
$1.7M more FCF
ICCC
$-1.8M
$-3.5M
CYCU
Faster 2-yr revenue CAGR
ICCC
ICCC
Annualised
ICCC
3.9%
-8.6%
CYCU

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CYCU
CYCU
ICCC
ICCC
Revenue
$3.5M
$5.5M
Net Profit
$-5.0M
$-139.7K
Gross Margin
12.1%
42.9%
Operating Margin
-141.7%
0.4%
Net Margin
-141.2%
-2.5%
Revenue YoY
-13.1%
-8.4%
Net Profit YoY
-546.8%
80.1%
EPS (diluted)
$-11.09
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CYCU
CYCU
ICCC
ICCC
Q4 25
$3.5M
Q3 25
$3.8M
$5.5M
Q2 25
$3.9M
$6.4M
Q1 25
$3.9M
$8.1M
Q4 24
$4.1M
$7.8M
Q3 24
$4.5M
$6.0M
Q2 24
$5.0M
$5.5M
Q1 24
$4.2M
$7.3M
Net Profit
CYCU
CYCU
ICCC
ICCC
Q4 25
$-5.0M
Q3 25
$-3.1M
$-139.7K
Q2 25
$-5.3M
$501.9K
Q1 25
$-10.2M
$1.4M
Q4 24
$1.1M
Q3 24
$116.1K
$-701.7K
Q2 24
$306.1K
$-1.5M
Q1 24
$-312.5K
$-437.9K
Gross Margin
CYCU
CYCU
ICCC
ICCC
Q4 25
12.1%
Q3 25
7.1%
42.9%
Q2 25
6.1%
43.7%
Q1 25
17.5%
41.6%
Q4 24
37.9%
36.5%
Q3 24
16.1%
26.3%
Q2 24
20.5%
22.5%
Q1 24
8.2%
31.6%
Operating Margin
CYCU
CYCU
ICCC
ICCC
Q4 25
-141.7%
Q3 25
-118.2%
0.4%
Q2 25
-96.9%
8.8%
Q1 25
-260.9%
13.9%
Q4 24
31.9%
8.0%
Q3 24
9.4%
-9.6%
Q2 24
14.6%
-25.3%
Q1 24
-0.8%
-4.1%
Net Margin
CYCU
CYCU
ICCC
ICCC
Q4 25
-141.2%
Q3 25
-81.5%
-2.5%
Q2 25
-136.1%
7.8%
Q1 25
-264.8%
17.9%
Q4 24
27.5%
Q3 24
2.6%
-11.7%
Q2 24
6.1%
-28.0%
Q1 24
-7.4%
-6.0%
EPS (diluted)
CYCU
CYCU
ICCC
ICCC
Q4 25
$-11.09
Q3 25
$-1.59
$-0.02
Q2 25
$-0.15
$0.06
Q1 25
$-0.56
$0.16
Q4 24
$1.56
$0.09
Q3 24
$0.11
$-0.09
Q2 24
$0.01
$-0.20
Q1 24
$-0.02
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CYCU
CYCU
ICCC
ICCC
Cash + ST InvestmentsLiquidity on hand
$5.3M
$3.9M
Total DebtLower is stronger
$9.5M
Stockholders' EquityBook value
$20.1M
$29.8M
Total Assets
$33.5M
$45.7M
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CYCU
CYCU
ICCC
ICCC
Q4 25
$5.3M
Q3 25
$3.7M
$3.9M
Q2 25
$1.0M
Q1 25
Q4 24
$38.7K
$3.8M
Q3 24
Q2 24
$1.3M
Q1 24
$960.3K
Total Debt
CYCU
CYCU
ICCC
ICCC
Q4 25
Q3 25
$9.5M
Q2 25
Q1 25
$8.7M
Q4 24
$9.0M
Q3 24
$9.4M
Q2 24
$9.8M
Q1 24
$10.2M
Stockholders' Equity
CYCU
CYCU
ICCC
ICCC
Q4 25
$20.1M
Q3 25
$19.1M
$29.8M
Q2 25
$14.0M
$29.9M
Q1 25
$12.9M
$29.0M
Q4 24
$3.5M
$27.5M
Q3 24
$-3.7M
$26.4M
Q2 24
$-3.4M
$23.5M
Q1 24
$-2.8M
$24.6M
Total Assets
CYCU
CYCU
ICCC
ICCC
Q4 25
$33.5M
Q3 25
$32.3M
$45.7M
Q2 25
$30.7M
$46.7M
Q1 25
$31.5M
$45.6M
Q4 24
$25.6M
$45.1M
Q3 24
$2.9M
$44.4M
Q2 24
$2.7M
$41.9M
Q1 24
$3.1M
$43.1M
Debt / Equity
CYCU
CYCU
ICCC
ICCC
Q4 25
Q3 25
0.32×
Q2 25
Q1 25
0.30×
Q4 24
0.33×
Q3 24
0.36×
Q2 24
0.42×
Q1 24
0.41×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CYCU
CYCU
ICCC
ICCC
Operating Cash FlowLast quarter
$-3.3M
$-1.2M
Free Cash FlowOCF − Capex
$-3.5M
$-1.8M
FCF MarginFCF / Revenue
-98.8%
-32.3%
Capex IntensityCapex / Revenue
5.3%
10.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-12.5M
$715.4K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CYCU
CYCU
ICCC
ICCC
Q4 25
$-3.3M
Q3 25
$-2.5M
$-1.2M
Q2 25
$-3.6M
$1.6M
Q1 25
$-2.7M
$1.6M
Q4 24
$-205.7K
$-3.1K
Q3 24
$-315.2K
$-639.3K
Q2 24
$-578.0K
$581.8K
Q1 24
$-272.4K
$418.5K
Free Cash Flow
CYCU
CYCU
ICCC
ICCC
Q4 25
$-3.5M
Q3 25
$-2.6M
$-1.8M
Q2 25
$-3.7M
$1.4M
Q1 25
$-2.8M
$1.2M
Q4 24
$-310.7K
$-199.3K
Q3 24
$-420.2K
$-727.7K
Q2 24
$-711.0K
$471.0K
Q1 24
$-377.4K
$348.1K
FCF Margin
CYCU
CYCU
ICCC
ICCC
Q4 25
-98.8%
Q3 25
-66.9%
-32.3%
Q2 25
-94.2%
22.4%
Q1 25
-72.7%
15.4%
Q4 24
-7.6%
-2.6%
Q3 24
-9.4%
-12.1%
Q2 24
-14.2%
8.6%
Q1 24
-8.9%
4.8%
Capex Intensity
CYCU
CYCU
ICCC
ICCC
Q4 25
5.3%
Q3 25
2.5%
10.8%
Q2 25
2.7%
2.4%
Q1 25
1.8%
4.1%
Q4 24
2.6%
2.5%
Q3 24
2.4%
1.5%
Q2 24
2.7%
2.0%
Q1 24
2.5%
1.0%
Cash Conversion
CYCU
CYCU
ICCC
ICCC
Q4 25
Q3 25
Q2 25
3.19×
Q1 25
1.09×
Q4 24
-0.18×
Q3 24
-2.71×
Q2 24
-1.89×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons